Preview Mode Links will not work in preview mode

Jan 11, 2024

Conversation around current considerations for use of GLP-1 RAs in people with type 2 diabetes and chronic kidney disease (CKD). The discussion will include general considerations for management of diabetes in CKD, potential benefits of GLP-1 RA therapy in CKD (e.g., glycemic lowering, CV risk reduction, potential kidney benefits), and a discussion of contemporary guideline recommendations for GLP-1 RA use in this population.

Claim CE and MOC Credit at https://bit.ly/4aNc3t8